Comparison · NCT02578641-sae
Chemo + EBV-CTL vs Chemo Only: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Chemo + EBV-CTL vs Chemo Only: serious adverse events. Trial comparisons, record NCT02578641-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02578641-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.417 | 0.344 | 0.494 | wilson | |
| Risk in group 2 | 0.284 | 0.22 | 0.358 | wilson | |
| Risk difference, group 1 minus group 2 | 0.133 | 0.0295 | 0.233 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.47 | 1.08 | 1.99 | log | |
| Odds ratio, group 1 over group 2 | 1.81 | 1.14 | 2.87 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Chemo + EBV-CTL than on Chemo Only | 7.51 | 4.29 | 33.9 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Chemo + EBV-CTL | gemcitabine+carboplatin + EBV-CTL | 68 | 163 | EG000 |
| Group 2 | Chemo Only | gemcitabine+carboplatin | 46 | 162 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events during the entire trial duration were monitored/assessed from randomization to end of treatment (approximately 13 months for Chemo+EBV-CTL and 6 months for Chemo Only).
Source ClinicalTrials.gov
Trial
- Title
- A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients
- NCT number
- NCT02578641
- Phases
- PHASE3
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- autologous EBV specific Cytotoxic T cells, combination IV gemcitabine and IV carboplatin (AUC2)
- Lead sponsor
- Tessa Therapeutics
- Results first posted
- 2023-06-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02578641?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02578641-sae